Inclusion Criteria:  Histologic diagnosis of breast cancer Metastatic or incurable Prior treatment with an anastrozole or letrozole and a CDK4/6 inhibitor Progression while on or within 6 months of stopping the CDK4/6 inhibitor At least one lesion amenable to percutaneous biopsy that is not a purely sclerotic bone lesion ECOG 0-2 Age 18 or greater Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.  Exclusion Criteria:  Prior treatment within 2 years with fulvestrant, alpelisib, everolimus, or capecitabine Comorbid disease other than breast cancer with a life expectancy of less than 2 years Cancer other than breast cancer that is expected to need treatment within 2 years Platelets < 100,000/microliter INR > 1.5